Abstract: Disclosed are oxadiazole compounds and pharmaceutically acceptable salts thereof. The compounds and pharmaceutically acceptable salts thereof are specifically suitable for the treatment of neurological diseases such as epilepsy.

Abstract: Disclosure relates to an electrochemical membrane degassing apparatus including a liquid channel in which raw water flows, a gaseous channel in which gas degassed from the raw water flows, a gas separation membrane allowing gas in the raw water to be moved to the gaseous channel, a surface modification layer formed at the gas separation membrane, and a power supply unit applying power to the surface modification layer, and selectively operated in either of a first process mode applying a low voltage power and a second process mode applying a high voltage power, wherein in the first process mode, an electrostatic repulsive force is generated between the surface modification layer and organic particles, and in the second process mode, a radical is generated, and the organic particles is oxidized by the radical. Accordingly, the efficiency of membrane degassing can be improved and membrane contamination can be prevented.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating a muscular disease or cachexia, comprising, as an active ingredient, a miRNA located in Dlk1-Dio3 cluster or a variant thereof. In the present invention, it has been found that expression of miRNAs located in the Dlk1-Dio3 cluster is decreased as age increases. In particular, in a case where most of the miRNAs are over-expressed in fully differentiated myotubes, it has been confirmed that the diameter of the myotubes increases. In addition, also in a tumor-induced cachexia mouse model, it has been confirmed that cachexia was improved by inhibiting Atrogin-1 protein. Accordingly, the miRNA located in the Dlk1-Dio3 cluster or a variant thereof can be usefully utilized for the treatment and prevention of an Atrogin-1-dependent muscular disease and cachexia.